Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes extensive molecular simulations of the target protein alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that considers conformational mobility in both free and complex states. Potential binding pockets are examined on the protein-protein interaction interface and in distant allosteric sites to cover all possible mechanisms of action.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P61244

UPID:
MAX_HUMAN

ALTERNATIVE NAMES:
Class D basic helix-loop-helix protein 4; Myc-associated factor X

ALTERNATIVE UPACC:
P61244; A6NH73; A8K265; A8K4G4; A8K824; P25912; P52163; Q14803; Q96CY8

BACKGROUND:
The Protein max, or Myc-associated factor X, is a transcription regulator that binds DNA in a sequence-specific manner alongside MYC or MAD. This binding influences gene expression, with the MYC:MAX complex enhancing transcription and the MAD:MAX complex inhibiting it. The repression of transcription is possibly mediated by a chromatin remodeling complex that includes H3 'Lys-9' histone methyltransferase activity, which in turn represses MYC transcriptional activity from E-box elements.

THERAPEUTIC SIGNIFICANCE:
Given its association with Pheochromocytoma, a tumor characterized by abnormal catecholamine production leading to hypertension, Protein max represents a critical target for therapeutic intervention. The exploration of Protein max's function and its genetic variants offers promising avenues for developing treatments for diseases where catecholamine regulation is disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.